Last updated on September 2013

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lymphoma | Pain | Myelodysplastic/Myeloproliferative Neoplasms | Neuroblastoma | Ovarian Cancer | Leukemia | Myelodysplastic Syndromes | Oral Complications | Kidney Cancer | Chronic Myeloproliferative Disorders | Sarcoma | Multiple Myeloma and Plasma Cell Neoplasm
  • Age: Between 2 - 18 Years
  • Gender: Male or Female
  • Other:
    DISEASE CHARACTERISTICS:
    Patients undergoing a myeloablative conditioning regimen comprising chemotherapy with
    or without radiotherapy prior to a first allogeneic bone marrow transplantation
    PATIENT CHARACTERISTICS:
    Age:
    2 to 18
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    Pulmonary:
    No pulmonary dysfunction that would increase significantly the risk of requiring
    intubation during the first 21 days after transplantation
    Other:
    Not pregnant
    Negative pregnancy test
    Fertile patients must use effective contraception
    No photophobia
    Must have emotional, cognitive, and mental maturity sufficient to tolerate
    light-emitting diode therapy application and oral examination without combativeness
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    See Disease Characteristics
    Chemotherapy:
    See Disease Characteristics
    Endocrine therapy:
    Not specified
    Radiotherapy:
    See Disease Characteristics
    Surgery:
    Not specified
    Other:
    No concurrent medication that may cause epidermal or ocular photosensitivity
    DISEASE CHARACTERISTICS:
    Patients undergoing a myeloablative conditioning regimen comprising chemotherapy with
    or without radiotherapy prior to a first allogeneic bone marrow transplantation
    PATIENT CHARACTERISTICS:
    Age:
    2 to 18
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    Pulmonary:
    No pulmonary dysfunction that would increase significantly the risk of requiring
    intubation during the first 21 days after transplantation
    Other:
    Not pregnant
    Negative pregnancy test
    Fertile patients must use effective contraception
    No photophobia
    Must have emotional, cognitive, and mental maturity sufficient to tolerate
    light-emitting diode therapy application and oral examination without combativeness
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    See Disease Characteristics
    Chemotherapy:
    See Disease Characteristics
    Endocrine therapy:
    Not specified
    Radiotherapy:
    See Disease Characteristics
    Surgery:
    Not specified
    Other:
    No concurrent medication that may cause epidermal or ocular photosensitivity
    DISEASE CHARACTERISTICS:
    Patients undergoing a myeloablative conditioning regimen comprising chemotherapy with
    or without radiotherapy prior to a first allogeneic bone marrow transplantation
    PATIENT CHARACTERISTICS:
    Age:
    2 to 18
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    Pulmonary:
    No pulmonary dysfunction that would increase significantly the risk of requiring
    intubation during the first 21 days after transplantation
    Other:
    Not pregnant
    Negative pregnancy test
    Fertile patients must use effective contraception
    No photophobia
    Must have emotional, cognitive, and mental maturity sufficient to tolerate
    light-emitting diode therapy application and oral examination without combativeness
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    See Disease Characteristics
    Chemotherapy:
    See Disease Characteristics
    Endocrine therapy:
    Not specified
    Radiotherapy:
    See Disease Characteristics
    Surgery:
    Not specified
    Other:
    No concurrent medication that may cause epidermal or ocular photosensitivity
    DISEASE CHARACTERISTICS:
    Patients undergoing a myeloablative conditioning regimen comprising chemotherapy with
    or without radiotherapy prior to a first allogeneic bone marrow transplantation
    PATIENT CHARACTERISTICS:
    Age:
    2 to 18
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    Pulmonary:
    No pulmonary dysfunction that would increase significantly the risk of requiring
    intubation during the first 21 days after transplantation
    Other:
    Not pregnant
    Negative pregnancy test
    Fertile patients must use effective contraception
    No photophobia
    Must have emotional, cognitive, and mental maturity sufficient to tolerate
    light-emitting diode therapy application and oral examination without combativeness
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    See Disease Characteristics
    Chemotherapy:
    See Disease Characteristics
    Endocrine therapy:
    Not specified
    Radiotherapy:
    See Disease Characteristics
    Surgery:
    Not specified
    Other:
    No concurrent medication that may cause epidermal or ocular photosensitivity
    DISEASE CHARACTERISTICS:
    Patients undergoing a myeloablative conditioning regimen comprising chemotherapy with
    or without radiotherapy prior to a first allogeneic bone marrow transplantation
    PATIENT CHARACTERISTICS:
    Age:
    2 to 18
    Performance status:
    Not specified
    Life expectancy:
    Not specified
    Hematopoietic:
    Not specified
    Hepatic:
    Not specified
    Renal:
    Not specified
    Pulmonary:
    No pulmonary dysfunction that would increase significantly the risk of requiring
    intubation during the first 21 days after transplantation
    Other:
    Not pregnant
    Negative pregnancy test
    Fertile patients must use effective contraception
    No photophobia
    Must have emotional, cognitive, and mental maturity sufficient to tolerate
    light-emitting diode therapy application and oral examination without combativeness
    PRIOR CONCURRENT THERAPY:
    Biologic therapy:
    See Disease Characteristics
    Chemotherapy:
    See Disease Characteristics
    Endocrine therapy:
    Not specified
    Radiotherapy:
    See Disease Characteristics
    Surgery:
    Not specified
    Other:
    No concurrent medication that may cause epidermal or ocular photosensitivity

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.